Biotech Values

[DewDiligence]

OHRP reverse merges into NeuBase Therapeutics:

https://globenewswire.com/news-release/2019/01/03/1679985/0/en/Ohr-Pharmaceutical-Inc-Announces-Merger-Agreement-with-NeuBase-Therapeutics-Inc.html

The proposed merger will create a public company focused on advancing NeuBase’s peptide-nucleic acid (PNA) antisense oligonucleotide (PATrOL) technology platform for the development of therapies to address severe and currently untreatable diseases caused by genetic mutations.

Upon closing of the transaction, the combined company will change its name to “NeuBase Therapeutics, Inc.” and propose its trading symbol on the NASDAQ be changed to “NBSE”. The executive team of NeuBase will serve as the executive team of the combined company, led by Dietrich A. Stephan, Ph.D. as Chief Executive Officer.

…current Ohr stockholders will own approximately 20% of the combined company and NeuBase stockholders will own approximately 80% of the combined company, after accounting for the additional NeuBase financing transaction…